Peak antifactor xa activity produced by dalteparin treatment in patients with renal impairment compared with controls.
作者： Adam R. Shprecher , Angela Cheng-Lai , Eileen M. Madsen , Hillel W. Cohen , Mark J. Sinnett
DOI: 10.1592/PHCO.2005.25.6.817
关键词: In patient 、 Dialysis 、 Control subjects 、 Impaired renal function 、 Urology 、 Medicine 、 Statistical significance 、 Physical therapy 、 Prospective cohort study 、 Antifactor xa 、 Low molecular weight heparin
摘要: Study Objective. To evaluate the relationship between impaired renal function and antifactor Xa activity in patients receiving dalteparin. Design. Open-label prospective study. Setting. Inpatient outpatient units of a large teaching hospital. Subjects. Eleven with impairment 11 control subjects normal function. Intervention. Subjects were administered dalteparin at dosage approximately 100 U/kg subcutaneously every 12 hours. Measurements Main Results. Peak steady-state levels compared groups. Mean ± SD similar for without impairment: 0.47 0.25 0.55 0.20 U/ml, respectively. A test equivalency showed statistical significance (p=0.0001). Conclusion. No meaningful difference peak was found subjects. extent that can be used as markers adjusting doses dalteparin, these data suggest such adjustments are not necessary who dialysis.
elsevier.com
pharmacotherapyjournal.org
researchgate.net 参考文章(29)
M Palm, Ch Mattsson, Pharmacokinetics of heparin and low molecular weight heparin fragment (Fragmin) in rabbits with impaired renal or metabolic clearance. Thrombosis and Haemostasis. ,vol. 58, pp. 932- 935 ,(1987) , 10.1055/S-0038-1646018
M Laposata, R C Sosolik, E M Van Cott, D Green, S H Goodnight, T W Barrowcliffe, College of American Pathologists Conference XXXI on laboratory monitoring of anticoagulant therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Archives of Pathology & Laboratory Medicine. ,vol. 122, pp. 799- 807 ,(1998)
Donald W. Cockcroft, Henry Gault, Prediction of Creatinine Clearance from Serum Creatinine Nephron. ,vol. 16, pp. 31- 41 ,(1976) , 10.1159/000180580
Knut-Olaf Haustein, Pharmacokinetic and Pharmacodynamic Properties of Oral Anticoagulants, Especially Phenprocoumon Seminars in Thrombosis and Hemostasis. ,vol. 25, pp. 5- 11 ,(1999) , 10.1055/S-2007-996417
Bernard Boneu, Claudine Caranobe, Yves Cadroy, Frederique Dol, Anne-Marie Gabaig, Dominique Dupouy, Pierre Sie, Pharmacokinetic Studies of Standard Unfractionated Heparin, and Low Molecular Weight Heparins in the Rabbit Seminars in Thrombosis and Hemostasis. ,vol. 14, pp. 18- 27 ,(1988) , 10.1055/S-2007-1002751
Jack Hirsh, Theodore E. Warkentin, Stephen G. Shaughnessy, Sonia S. Anand, Jonathan L. Halperin, Robert Raschke, Christopher Granger, E. Magnus Ohman, James E. Dalen, Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety Chest. ,vol. 119, pp. 64- ,(2001) , 10.1378/CHEST.119.1_SUPPL.64S
C. Goudable, S. Saivin, G. Houin, P. Sie, B. Boneu, H. Tonthat, J.M. Suc, Pharmacokinetics of a low molecular weight heparin (Fraxiparine) in various stages of chronic renal failure. Nephron. ,vol. 59, pp. 543- 545 ,(1991) , 10.1159/000186641
C. Caranobe, A. Barret, A.M. Gabaig, D. Dupouy, P. Sié, B. Boneu, Disappearance of circulating anti-Xa activity after intravenous injection of standard heparin and of a low molecular weight heparin (CY 216) in normal and nephrectomized rabbits Thrombosis Research. ,vol. 40, pp. 129- 133 ,(1985) , 10.1016/0049-3848(85)90357-3
B. Hory, M.H. Claudet, J. Magnette, P. Bechtel, B. Bayrou, Pharmacokinetic of a very low molecular weight heparin in chronic renal failure. Thrombosis Research. ,vol. 63, pp. 311- 317 ,(1991) , 10.1016/0049-3848(91)90134-I
M. D. Laforest, N. Colas-Linhart, F. Guiraud-Vitaux, B. Bok, L. Bara, M. Samama, J. Marin, F. Imbault, A. Uzan, Pharmacokinetics and biodistribution of technetium 99m labelled standard heparin and a low molecular weight heparin (enoxaparin) after intravenous injection in normal volunteers. British Journal of Haematology. ,vol. 77, pp. 201- 208 ,(1991) , 10.1111/J.1365-2141.1991.TB07978.X